|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.65 TWD | -0.24% |
|
-1.20% | -18.38% |
| 04-15 | Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only | CI |
| 03-21 | Applied BioCode Announces CEO Changes | CI |
Applied BioCode Corporation reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was TWD 319.96 million compared to TWD 299.02 million a year ago. Net loss was TWD 165.2 million compared to TWD 103.5 million a year ago.
Basic loss per share from continuing operations was TWD 2.02 compared to TWD 1.33 a year ago. Diluted loss per share from continuing operations was TWD 2.02 compared to TWD 1.33 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.38% | 52.58M | |
| -36.44% | 9.2B | |
| -3.29% | 3.12B | |
| +19.31% | 2.8B | |
| -18.71% | 2.07B | |
| -22.03% | 1.59B | |
| +64.58% | 1.44B | |
| +34.58% | 830M | |
| -7.42% | 724M | |
| -25.51% | 507M |
APPLIED BIOCODE CORPORATION 
